Review Article
Review of Routine Laboratory Monitoring for Patients with Rheumatoid Arthritis Receiving Biologic or Nonbiologic DMARDs
Table 5
Proportions of patients who experienced decreases in platelet counts during RA treatment in clinical .
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
DMARD, disease-modifying antirheumatic drug; N/A, not available; RA, rheumatoid arthritis; grades were defined as follows: grade 2, 50,000 to <75,000 cells/mm3; grade 3, 25,000 to <50,000 cells/mm3; grade 4, <25,000 cells/mm3. are the proportions of patients experiencing grade 3 or 4 platelet counts except where noted. data were available for sulfasalazine, hydroxychloroquine/chloroquine, certolizumab, etanercept, or tofacitinib. received leflunomide plus infliximab. medical letter (personal communication), data on file. |